{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:23:39Z","timestamp":1789885419461,"version":"4.0.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited promising responses and an acceptable toxicity profile in patients with relapsed and\/or refractory multiple myeloma (R\/R MM). In the present phase 2, multicenter, open-label study, 129 bortezomib-naive patients with R\/R MM (median of 2 prior therapies) were separated into Cohort 1, scheduled to receive intravenous carfilzomib 20 mg\/m2 for all treatment cycles, and Cohort 2, scheduled to receive 20 mg\/m2 for cycle 1 and then 27 mg\/m2 for all subsequent cycles. The primary end point was an overall response rate (\u2265 partial response) of 42.4% in Cohort 1 and 52.2% in Cohort 2. The clinical benefit response (overall response rate + minimal response) was 59.3% and 64.2% in Cohorts 1 and 2, respectively. Median duration of response was 13.1 months and not reached, and median time to progression was 8.3 months and not reached, respectively. The most common treatment-emergent adverse events were fatigue (62.0%) and nausea (48.8%). Single-agent carfilzomib elicited a low incidence of peripheral neuropathy\u201417.1% overall (1 grade 3; no grade 4)\u2014in these pretreated bortezomib-naive patients. The results of the present study support the use of carfilzomib in R\/R MM patients. This trial is registered at www.clinicaltrials.gov as NCT00530816.<\/jats:p>","DOI":"10.1182\/blood-2012-03-414359","type":"journal-article","created":{"date-parts":[[2012,5,4]],"date-time":"2012-05-04T04:48:05Z","timestamp":1336106885000},"page":"5661-5670","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":204,"title":["An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma"],"prefix":"10.1182","volume":"119","author":[{"given":"Ravi","family":"Vij","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kukreti","sequence":"additional","affiliation":[{"name":"University of Toronto Princess Margaret Hospital, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"McDonagh","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine, Lexington, KY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, AB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic J.","family":"Reu","sequence":"additional","affiliation":[{"name":"Taussig Cancer Center, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashat Y.","family":"Gabrail","sequence":"additional","affiliation":[{"name":"Gabrail Cancer Center, Canton, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[{"name":"University of Alberta Cross Cancer Institute, Edmonton, AB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[{"name":"Colorado Blood Cancer Institute, Denver, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lee","sequence":"additional","affiliation":[{"name":"Tower Cancer Research Foundation, Beverly Hills, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rosen","sequence":"additional","affiliation":[{"name":"Roy and Patricia Disney Family Cancer Center, Providence Saint Joseph Medical Center, Burbank, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[{"name":"Royal Victoria Hospital, Montreal, QC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Kunkel","sequence":"additional","affiliation":[{"name":"Independent consultant, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Wear","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Consortium, Norwalk, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin F.","family":"Wong","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111808584431500_B1","volume-title":"Cancer Facts & Figures 2012","author":"American Cancer Society","year":"2012"},{"issue":"10","key":"2019111808584431500_B2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.6004\/jnccn.2011.0098","article-title":"Management of relapsed and relapsed\/refractory multiple myeloma.","volume":"9","author":"Laubach","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2019111808584431500_B3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010.","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2019111808584431500_B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2009.01.001","article-title":"Multiple myeloma.","volume":"33","author":"Rajkumar","year":"2009","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"2019111808584431500_B5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/jm7010589","article-title":"Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.","volume":"51","author":"Dorsey","year":"2008","journal-title":"J Med Chem"},{"issue":"4","key":"2019111808584431500_B6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.mam.2009.04.001","article-title":"The proteasomal system.","volume":"30","author":"Jung","year":"2009","journal-title":"Mol Aspects Med"},{"issue":"1","key":"2019111808584431500_B7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"2019111808584431500_B8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/jnci\/djr160","article-title":"Novel proteasome inhibitors to overcome bortezomib resistance.","volume":"103","author":"Ruschak","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2019111808584431500_B9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"issue":"13","key":"2019111808584431500_B10","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"issue":"16","key":"2019111808584431500_B11","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111808584431500_B12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","article-title":"The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.","volume":"136","author":"Stapnes","year":"2007","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111808584431500_B13","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1182\/blood-2009-12-257261","article-title":"The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.","volume":"115","author":"Dasmahapatra","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111808584431500_B14","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111808584431500_B15","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111808584431500_B16","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2019111808584431500_B17","first-page":"985","article-title":"Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract].","volume":"116","author":"Siegel","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111808584431500_B18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111808584431500_B19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"issue":"15","key":"2019111808584431500_B20","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808584431500_B21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2019111808584431500_B22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2019111808584431500_B23","volume-title":"Common Terminology Criteria for Adverse Events Version 3.0","author":"Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health","year":"2006"},{"issue":"24","key":"2019111808584431500_B24","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111808584431500_B25","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111808584431500_B26","first-page":"1954","article-title":"Pooled safety analysis from phase 1 and 2 studies of carfilzomib (CFZ) in patients with relapsed and\/or refractory multiple myeloma (MM) [abstract].","volume":"116","author":"Singhal","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111808584431500_B27","first-page":"1876","article-title":"Integrated safety data from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract].","volume":"118","author":"Singhal","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111808584431500_B28","first-page":"430","article-title":"Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects [abstract].","volume":"114","author":"Vij","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111808584431500_B29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111808584431500_B30","first-page":"1953","article-title":"Long-term treatment and tolerability of the novel proteasome inhibitor carfilzomib (CFZ) in patients with relapsed and\/or refractory multiple myeloma (R\/R MM) [abstract].","volume":"116","author":"Jaganath","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111808584431500_B31","first-page":"2930","article-title":"A phase 1b\/2 study of prolonged infusion carfilzomib in patients with relapsed and\/or refractory (R\/R) multiple myeloma: updated efficacy and tolerability from the completed 20\/56 mg\/m2 expansion cohort of PX-171-007 [abstract].","volume":"118","author":"Papadopoulos","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111808584431500_B32","article-title":"PX-171-006, A phase IB dose-escalation study of carfilzomib + lenalidomide + low-dose dexamethasone in relapsed and\/or refractory multiple myeloma [abstract].","volume":"95","author":"Wang","year":"2010","journal-title":"Haematologica"},{"issue":"21","key":"2019111808584431500_B33","first-page":"1877","article-title":"Multivariate modelling reveals evidence of a dose-response relationship in phase 2 studies of single-agent carfilzomib [abstract].","volume":"118","author":"Squifflet","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/24\/5661\/1497076\/zh802412005661.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/24\/5661\/1497076\/zh802412005661.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:03:20Z","timestamp":1574089400000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/24\/5661\/30289\/An-openlabel-singlearm-phase-2-PX171004-study-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,14]]},"references-count":33,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-414359","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,14]]}}}